Literature DB >> 10428922

A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.

R Falk1, A J Domb, I Polacheck.   

Abstract

New, stable, highly water-soluble, nontoxic polysaccharide conjugates of amphotericin B (AmB) are described. AmB was conjugated by a Schiff-base reaction with oxidized arabinogalactan (AG). AG is a highly branched natural polysaccharide with unusual water solubility (70% in water). A high yield of active AmB was obtained with the conjugates which were similarly highly water soluble and which could be appropriately formulated for injection. They showed comparable MICs for Candida albicans and Cryptococcus neoformans (MICs, 0.1 to 0.2 microg/ml). The reduced AmB conjugate, which was synthesized at pH 11 for 48 h at 37 degrees C, was nonhemolytic and was much safer than conventional micellar AmB-deoxycholate. It was the least toxic AmB-AG conjugate among those tested with mice (maximal tolerated dose, 50 mg/kg of body weight), and histopathology indicated no damage to the liver or kidneys. This conjugate, similarly to the liposomal formulation (AmBisome), was more effective than AmB-deoxycholate in prolonging survival. It was more effective than both the liposomal and the deoxycholate formulations in eradicating yeast cells from target organs. The overall results suggest that after further development of the AmB-AG conjugate, it may be a potent agent in the treatment of fungal infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428922      PMCID: PMC89400     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients.

Authors:  P O Gubbins; J L Bowman; S R Penzak
Journal:  Pharmacotherapy       Date:  1998 May-Jun       Impact factor: 4.705

Review 2.  Infectious complications in the cancer patient.

Authors:  G P Bodey
Journal:  Curr Probl Cancer       Date:  1977-06       Impact factor: 3.187

3.  Pharmacology, toxicity, and therapeutic usefulness of amphotericin B.

Authors:  W T Butler
Journal:  JAMA       Date:  1966-01-31       Impact factor: 56.272

Review 4.  Diagnosis and successful treatment of fusariosis in the compromised host.

Authors:  W G Merz; J E Karp; M Hoagland; M Jett-Goheen; J M Junkins; A F Hood
Journal:  J Infect Dis       Date:  1988-11       Impact factor: 5.226

Review 5.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 6.  Amphotericin B: 30 years of clinical experience.

Authors:  H A Gallis; R H Drew; W W Pickard
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients.

Authors:  G G Chabot; R Pazdur; F A Valeriote; L H Baker
Journal:  J Pharm Sci       Date:  1989-04       Impact factor: 3.534

Review 8.  Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.

Authors:  D W Denning
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

9.  Treatment of murine cryptococcosis with liposome-associated amphotericin B.

Authors:  J R Graybill; P C Craven; R L Taylor; D M Williams; W E Magee
Journal:  J Infect Dis       Date:  1982-05       Impact factor: 5.226

10.  Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes.

Authors:  D Forster; C Washington; S S Davis
Journal:  J Pharm Pharmacol       Date:  1988-05       Impact factor: 3.765

View more
  14 in total

1.  The in vitro characterization of polyene glycosyltransferases AmphDI and NysDI.

Authors:  Changsheng Zhang; Rocco Moretti; Jiqing Jiang; Jon S Thorson
Journal:  Chembiochem       Date:  2008-10-13       Impact factor: 3.164

2.  Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis.

Authors:  Joanna Boros-Majewska; Natalia Salewska; Edward Borowski; Sławomir Milewski; Sladjana Malic; Xiao-Qing Wei; Anthony J Hayes; Melanie J Wilson; David W Williams
Journal:  Med Microbiol Immunol       Date:  2014-06-13       Impact factor: 3.402

3.  Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.

Authors:  J Golenser; S Frankenburg; T Ehrenfreund; A J Domb
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

4.  Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.

Authors:  Rama Falk; Jacob Grunwald; Amnon Hoffman; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Toxicity mechanisms of amphotericin B and its neutralization by conjugation with arabinogalactan.

Authors:  Sarah Kagan; Diana Ickowicz; Miriam Shmuel; Yoram Altschuler; Edward Sionov; Miriam Pitusi; Aryeh Weiss; Shimon Farber; Abraham J Domb; Itzhack Polacheck
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  Injectable in situ cross-linking hydrogels for local antifungal therapy.

Authors:  Sarah P Hudson; Robert Langer; Gerald R Fink; Daniel S Kohane
Journal:  Biomaterials       Date:  2009-11-26       Impact factor: 12.479

8.  In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts.

Authors:  Anjan Debnath; Josefino B Tunac; Angélica Silva-Olivares; Silvia Galindo-Gómez; Mineko Shibayama; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen.

Authors:  Anjan Debnath; Josefino B Tunac; Silvia Galindo-Gómez; Angélica Silva-Olivares; Mineko Shibayama; James H McKerrow
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 10.  Biosynthesis and pathway engineering of antifungal polyene macrolides in actinomycetes.

Authors:  Dekun Kong; Mi-Jin Lee; Shuangjun Lin; Eung-Soo Kim
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-21       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.